Soldevila-Boixader, LauraVillanueva, BernatUlldemolins, MartaBenavent Palomares, EvaPadullés Zamora, AriadnaRibera Puig, AlbaBorras, IreneAriza Cardenal, JavierMurillo Rubio, Óscar2021-05-132021-05-132021-04-16https://hdl.handle.net/2445/177264Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14-24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.7 p.application/pdfengcc by (c) Soldevila et al., 2021http://creativecommons.org/licenses/by/3.0/es/PneumòniaMalalties bacterianes grampositivesPneumoniaGram-positive bacterial infectionsinfo:eu-repo/semantics/article7200142021-05-13info:eu-repo/semantics/openAccess33923382